Last Updated: 04/06/07

For More Details
about CIP

Visit the CIP Website

General Electric Healthcare

Website: http://www.gehealthcare.com/usen/index.html

NCI, through CIP, has entered into an agreement with General Electric Healthcare to develop the radiopharmaceutical imaging agent F-18 fluorodeoxythymidine for use with positron emission tomography (PET) in clinical trials. This agreement may serve as a template for similar projects. NCI and FDA are also working together to evaluate other approaches to implementing regulatory requirements governing the use of imaging agents.